SCHEMBL23985113

SCHEMBL23985113

O=C(Nc1cc(-c2ccc3ncnn3c2)nc2c1C(c1cc(F)ccc1Cl)NC2=O)c1cc(F)cc(C(F)(F)F)c1

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.35
TGFBR1 P36897 7/20 0.33
CSF1R P07333 1/20 0.33
AURKA O14965 1/20 0.33
CSNK1D P48730 2/20 0.32
CSNK1E P49674 2/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
MAPK14 Q16539 1/20 0.32
JAK2 O60674 3/20 0.32
SRC P12931 1/20 0.32
WDR5 P61964 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30305520 1.00 KDR (0.35) KDRTGFBR1CSF1RAURKACSNK1D
SCHEMBL30305562 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL30305516 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL30305451 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL23984567 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL30305561 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL23985000 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL23984566 0.88 KDR (0.36) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL23985793 0.86 KDR (0.35) KDRTGFBR1CSF1RAURKASLC6A2
SCHEMBL23985210 0.86 KDR (0.35) KDRTGFBR1CSF1RAURKASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230353959-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-11-02 US disclosed
WO-2021222556-A1 PI3K-α INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed